Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CHALOUNI, Mathieu | |
| dc.contributor.author | LOUBET, Paul | |
| hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | LHOMME, Edouard | |
| dc.contributor.author | NINOVE, Laetitia | |
| dc.contributor.author | BARROU, Benoit | |
| dc.contributor.author | BLAY, Jean-Yves | |
| dc.contributor.author | HOURMANT, Maryvonne | |
| dc.contributor.author | DE SEZE, Jérome | |
| dc.contributor.author | LAVILLE, Martine | |
| dc.contributor.author | LAVIOLLE, Bruno | |
| dc.contributor.author | LELIÈVRE, Jean-Daniel | |
| dc.contributor.author | MOREL, Jacques | |
| dc.contributor.author | QUOC, Stéphanie Nguyen | |
| dc.contributor.author | SPANO, Jean-Philippe | |
| dc.contributor.author | TERRIER, Benjamin | |
| dc.contributor.author | THIEBAUT, Anne | |
| dc.contributor.author | VIALLARD, Jean-Francois | |
| dc.contributor.author | VRTOVSNIK, François | |
| dc.contributor.author | CIRCOSTA, Sophie | |
| dc.contributor.author | BARQUIN, Aude | |
| dc.contributor.author | GHARIB, Mariam | |
| dc.contributor.author | TARTOUR, Eric | |
| dc.contributor.author | PARFAIT, Béatrice | |
| hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | THIEBAUT, Rodolphe | |
| dc.contributor.author | MEYER, Laurence | |
| dc.contributor.author | DE LAMBALLERIE, Xavier | |
| dc.contributor.author | LAUNAY, Odile | |
| hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| dc.date.accessioned | 2024-10-29T12:13:25Z | |
| dc.date.available | 2024-10-29T12:13:25Z | |
| dc.date.issued | 2024-09-27 | |
| dc.identifier.issn | 1471-2334 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202948 | |
| dc.description.abstractEn | We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection over the following six months in specific populations. ANRS0001SCOV-POPART is a French nationwide multicenter prospective observational cohort study assessing the immune response to Covid-19 vaccines routinely administered to 11 subgroups of patients with chronic disease and a control group. Participants from the ANRS0001S COV-POPART were included if they received at least two doses of Covid-19 vaccine for the primary vaccine course, had measurements of anti-Spike, anti-receptor binding domain (RBD) IgG-specific or neutralizing antibodies one month after the end of the primary vaccine course, without being infected by SARS-CoV-2 before the measurement. SARS-CoV-2 infections defined by a positive PCR/antigenic test or seroconversion to detectable anti nucleocapsid antibodies were evaluated until the first COVID-19 booster injection. Cox proportional hazards models taking into account interval-censored data were implemented to estimate the association between each antibody level and the risk of SARS-CoV-2 infection. Predictive performances were evaluated by the area under the receiving operating characteristic curve (AUROC). Two thousand five hundred seventy adults from a specific population and 1,123 from the control group were included. The cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement were 6.0% 95% confidence interval: [5.0; 7.9] and 10.1% 95% confidence interval: [8.3; 11.9], respectively. Higher levels of anti-Spike IgG antibody were associated with a lower risk of SARS-CoV-2 infections in the control group, but not in the specific populations. Among the specific populations, AUROC were 74.5%, 74.9%, and 72.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. AUROC were superior in the specific populations, 82.0%, 81.2%, and 81.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. Vaccine-induced antibody response after the primary course of Covid-19 infection only moderately discriminated between participants developing a SARS-CoV-2 infection during the Omicron wave. NCT04824651 (first posted: 2021-04-01). | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Humans | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Male | |
| dc.subject.en | Female | |
| dc.subject.en | Middle Aged | |
| dc.subject.en | Antibodies | |
| dc.subject.en | Viral | |
| dc.subject.en | COVID-19 Vaccines | |
| dc.subject.en | SARS-CoV-2 | |
| dc.subject.en | Prospective Studies | |
| dc.subject.en | Antibodies | |
| dc.subject.en | Neutralizing | |
| dc.subject.en | Aged | |
| dc.subject.en | Adult | |
| dc.subject.en | France | |
| dc.subject.en | Immunoglobulin G | |
| dc.subject.en | Biomarkers | |
| dc.subject.en | Spike Glycoprotein | |
| dc.subject.en | Coronavirus | |
| dc.subject.en | Cohort Studies | |
| dc.subject.en | Immunity | |
| dc.subject.en | Humoral | |
| dc.title.en | Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants | |
| dc.title.alternative | BMC Infect Dis | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s12879-024-09861-5 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 39333909 | en_US |
| bordeaux.journal | BMC Infectious Diseases | en_US |
| bordeaux.page | 1049 | en_US |
| bordeaux.volume | 24 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | INRIA | en_US |
| bordeaux.team | SISTM_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Recherches sur le Sida et les Hépatites Virales | en_US |
| bordeaux.import.source | pubmed | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Infectious%20Diseases&rft.date=2024-09-27&rft.volume=24&rft.issue=1&rft.spage=1049&rft.epage=1049&rft.eissn=1471-2334&rft.issn=1471-2334&rft.au=CHALOUNI,%20Mathieu&LOUBET,%20Paul&LHOMME,%20Edouard&NINOVE,%20Laetitia&BARROU,%20Benoit&rft.genre=article |
